Abbey Modlin
Nurse Practitioner · Des Moines, IANPI 1295253557
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,175 of the $12,167 with a category attached, or 75.4%. Abbott accounts for 88.3% of it on its own, with 11 other manufacturers making up the rest. Among nurse practitioner clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $243.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$11K
- Lilly USA, LLC$260
- Sanofi-aventis U.S. LLC$246
- Medtronic$234
- Insulet Corporation$220
- AstraZeneca$125
- plus $335 from 6 others
What the payments were for
- Consulting fees$5004%
- Speaking & faculty fees$9,17575%
- Travel & lodging$2412%
- Food & beverage$2,25119%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 29 | $10,747 |
| Lilly USA, LLC | 5 | $260 |
| Sanofi-aventis U.S. LLC | 4 | $246 |
| Medtronic | 3 | $234 |
| Insulet Corporation | 2 | $220 |
| AstraZeneca | 1 | $125 |
| Tandem Diabetes Care, Inc. | 1 | $121 |
| Bayer | 1 | $81 |
| Amgen | 1 | $69 |
| Nevro Corp. | 1 | $26 |
| BETA Bionics, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$10,213
- FreeStyle Libre 2$252
- FreeStyle Libre$229
- Omnipod$136
- FARXIGA$125
- SOLIQUA 100/33$122
- JARDIANCE$122
- t:slim X2 Insulin Pump with Control-IQ$121
- EMGALITY$112
- MINIMED 780G$111
How this compares
$12,167 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 797 | $951,657 |
| JardianceEmpagliflozin | 614 | $547,934 |
| MounjaroTirzepatide | 309 | $381,948 |
| Tresiba Flextouch U-200Insulin Degludec | 203 | $268,187 |
| TrulicityDulaglutide | 205 | $232,006 |
| Tresiba Flextouch U-100Insulin Degludec | 264 | $203,905 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 53 | $148,502 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 130 | $117,364 |
| Humalog Kwikpen U-100Insulin Lispro | 294 | $85,795 |
| Humulin R U-500Insulin Regular, Human | 23 | $79,177 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 126 | $73,011 |
| FarxigaDapagliflozin Propanediol | 75 | $72,617 |
| Novolog FlexpenInsulin Aspart | 249 | $71,901 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 110 | $66,665 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 396 | $65,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog, Tresiba | $17 | $1,010,854907 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $260 | $628,740622 claims |
| AstraZenecaFarxiga | $125 | $72,61775 claims |
| Sanofi-aventis U.S. LLCLantus | $246 | $5,70942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Other nurse practitioner in Des Moines
- Nicole MorganDes Moines$106K
- Theresa HohertzDes Moines$8K
- Blake WilliamsDes Moines$6K
- Noelle MundtDes Moines$6K
- Becky JohnsonDes Moines$6K
- Magdalena DawsonDes Moines$4K
- Maksim BlidchenkoDes Moines$4K
- Susan WilsonDes Moines$4K
- Angela PembrokeDes Moines$3K
- Blake StandiferDes Moines$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.